Last reviewed · How we verify
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis for this study is that at a dose with sufficient safety, the mean maximal glucose infusion rate (GIRmax) after single subcutaneous (SC) administration of MK-1092 in adult participants with T1DM is within an acceptable range. (Part 3)
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 69 |
| Start date | Wed Aug 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Nov 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Interventions
- MK-1092, 4.0 nmol/kg
- MK-1092, 8.0 nmol/kg
- MK-1092, 16 nmol/kg
- MK-1092, 32 nmol/kg
- MK-1092, 64 nmol/kg
- Glargine 3.0 nmol/kg
- Lispro 1.2 nmol/kg
- Placebo to glargine
- Placebo to MK-1092
- Dextrose
Countries
United States